Matt Zuga - Dec 29, 2022 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: CFO and Chief Business Officer
Signature: /s/ Katherine Denby, Attorney-in-Fact
Stock symbol: ABOS
Transactions as of: Dec 29, 2022
Transactions value $: $59,500
Form type: 4
Date filed: 1/3/2023, 04:23 PM
Previous filing: Jan 21, 2022
Next filing: Jan 18, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABOS	Common Stock	Options Exercise	$59.5K	+50K	+190.93%	$1.19^*	76.2K	Dec 29, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Stock Option (right to buy)	Options Exercise	$0	-50K	-11.08%	$0.00	401K	Dec 29, 2022	Common Stock	50K	$1.19	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares underlying the option vested and became exercisable on January 1, 2022; the remainder vested or shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.